Treatment

Gardasil 9 suspension for injection. Human Papillomavirus 9-valent Vaccine (Recombinant clinical trials

3 indexed studies · 0 currently recruiting

Ongoing, recruitingTherapeutic confirmatory (Phase III)
Phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy of pre-surgical HPV9-valente vaccination in women treated with loop electrosurgical excision (LEEP) for high-grade cervical intraepithelial neoplasia (CIN2+) up to cervical cancer initially invasive (FIGO IA1) - HOPE 9 STUDY
This study looks at whether a special HPV vaccine, Gardasil 9, can help prevent cervical cell changes from coming back in women who've had surgery. It compares vaccinated women to those who received a dummy treatment.
For: cervical cancer
Italy
AuthorisedPhase III and phase IV (Integrated)
Prospective longitudinal study on immunogenicity, induction of cellular immune responses and safety of vaccination against HPV with the 9valent vaccine in HIV-positive women The Papillon study
This study looks at how well a vaccine called Gardasil 9 works for women with HIV. It checks if the vaccine helps their bodies fight against HPV, a common virus that can cause certain cancers. Researchers want to see if it's safe and effective for this group.
For: giving a commercially available vaccine to women with HIV under treatment · women living with HIV traeted by antiretroviral
Belgium
AuthorisedTherapeutic confirmatory (Phase III)
Multicenter, randomized, double-blinded, placebo-controlled phase 3 trial to evaluate nonavalent HPV vaccine as a secondary prevention in patients treated for human papilloma virus related high-grade squamous intraepithelial lesions.(BioHPV)
This study looks at whether a special HPV vaccine can stop abnormal cell changes from coming back after treatment. It's for people aged 18 and over who have had these changes, sometimes called HSIL, in areas like the cervix, vulva, or anus. The vaccine being tested is Gardasil 9.
For: Patients with primary HPV high-grade squamous intra-epithelial lesions (HSIL) at any site (vulvar VIN · vaginal VaIN · penile (PeIN)
France

Prospective longitudinal study on immunogenicity, induction of cellular immune responses and safety of vaccination against HPV with the 9valent vaccine in HIV-positive women The Papillon study

Multicenter, randomized, double-blinded, placebo-controlled phase 3 trial to evaluate nonavalent HPV vaccine as a secondary prevention in patients treated for human papilloma virus related high-grade squamous intraepithelial lesions.(BioHPV)